OCUP News and Press, Ocuphire Pharma Inc Com From 11/01/21

FDA Approves First Pharmaceutical Therapy to Treat Presbyopia; Nyxol on Track to Start Phase 3 Presbyopia Trials in First Half of 2022 Ocuphire Uniquely Positioned in Developing Late-Stage Innovative Therapies for Retinal Disease and Presbyopia FARMINGTON HILLS, Mich., Nov...

The following slide deck was published by Ocuphire Pharma, Inc. in conjunction with this event. For further details see: Ocuphire Pharma (OCUP) Investor presentation - Slideshow

New Review Publications Underscore the Role of the APE1/Ref-1 Protein in Multiple Pro-angiogenic Pathways Associated with Neovascular Eye Disease Including Diabetic Retinal Diseases and Age-Related Macular Degeneration Ocuphire’s Phase 2 ZETA-1Trial Evaluating APX3330 (an O...

FARMINGTON HILLS, Mich., Oct. 01, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinical-stage ophthalmic biopharmaceutical company focused on developing and commercializing therapies for the treatment of several eye disorders, today announced that its clinical-stage, nov...

Benzinga Healthcare Small Cap Conference on September 29-30, 2021 Ophthalmology Futures Forums: European Virtual Forum on October 7, 2021 Alliance Global Partners Biotech & Specialty Pharma Conference on October 13, 2021 FARMINGTON HILLS, Mich., Sept. 27, 2021 ...

Euro Forums 2021 Virtual Retina Forum on September 8, 2021 HC Wainwright Virtual 23 rd Annual Global Investment Conference on September 13-15, 2021 Oppenheimer Virtual Fall Healthcare Life Sciences & Med Tech Summit on September 20-23, 2021 Cantor V...

Ocuphire Pharma (NASDAQ:OCUP): Q2 GAAP EPS of -$0.52 misses by $0.08. Revenue of $0.1M. As of June 30, 2021, the Company had cash and cash equivalents of approximately $24.2 million. Press Release For further details see: Ocuphire Pharma EPS misses by $0.08

Continued Momentum in Nyxol ® Programs with Announcement of Positive Top-Line Results from VEGA-1 Phase 2 Trial in Presbyopia Nyxol plus Low-Dose Pilocarpine Phase 2 Trial Results Show Potential for Best-in-Class Presbyopia Drug Profile in Data Presentat...

Canaccord Genuity 41 st Annual Growth Conference being held virtually on August 10-12, 2021 HC Wainwright Ophthalmology Virtual Conference on August 17, 2021 FARMINGTON HILLS, Mich., Aug. 06, 2021 (GLOBE NEWSWIRE) -- Ocuphire Pharma, Inc. (Nasdaq: OCUP), a clinic...

Ocuphire is positioning itself as a leading ophthalmic player, providing novel therapeutic solutions for both front and back of the eye indications. The company recently announced positive topline results for its lead candidate, Nyxol, in a Phase 3 study for Reversal of Mydriasis (RM)...